Molecular Variations Based on Isosteric Replacements

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 175-188

  Wermuth, Camille G ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL PROPERTIES; ELECTRONIC STRUCTURE; QUANTUM THEORY;

ACTIVE MOLECULES; ELECTRONIC DISTRIBUTION; ISOSTERIC MOLECULES; MEDICINAL CHEMISTRY; MOLECULAR LEVELS; MOLECULAR VARIATION; PHYSICAL AND CHEMICAL PROPERTIES; QUANTUM-MECHANICAL THEORY;

MOLECULES;

EID: 84942926254     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50017-9     Document Type: Chapter

References (139)

1. Langmuir I. Isomorphism, isosterism and covalence. J. Am. Chem. Soc. 1919, 41:1543-1559.
2. Friedman H.L. Influence of isosteric replacements upon biological activity. Symposium on Chemical-Biological Correlation 1951, National Research Council Publication, New York.
3. Grimm H.G. Über bau und grösse der nichtmetallhydride. Z. Elektrochem 1925, 31:474-480.
4. Grimm H.G. The system of chemical compounds from the viewpoint of atom research, several problems of experimental research. Part I. Naturwissenschaften 1929, 17:535-540.
5. Grimm H.G. The system of chemical compounds from the viewpoint of atom research, several problems of experimental research. Part II. Naturwissenschaften 1929, 17:557-564.
6. Erlenmeyer H., Leo M. Über pseudoatome. Helv. Chim. Acta 1932, 15:1171-1186.
7. Erlenmeyer H. Les composés isostères et le problème de la resemblance en chimie. Bull. Soc. Chim. Biol. 1948, 30:792-805.
8. Thornber C.W. Isosterism and molecular modification in drug design. Chem. Soc. Rev. 1979, 8:563-580.
9. Krogsgaard-Larsen P., Hjeds H., Falch E., Jørgensen F.S., Nielsen L. Recent advances in GABA agonists, antagonists and uptake inhibitors: structure-activity relationships and therapeutic potential. Advances in Drug Research 1988, 381-456. Academic Press, Washington, DC. B. Testa (Ed.).
10. Janssen, P.A.J. and Van der Eycken, C.A.M. The chemical anatomy of potent morphine-like analgesics. Drugs Affecting the Central Nervous System, pp. 25-60. Marcel Dekker, New York.
11. Boyle E.A., Mangan F.R., Markwell R.E., Smith S.A., Thomson M.J., et al. 7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents. J. Med. Chem. 1986, 29:894-898.
12. Morgan B.P., Scholtz J.M., Ballinger M.D., Zipkin I.D., Bartlett P.A. Differential binding energy: a detailed evaluation of the influence of hydrogen bonding and hydrophobic groups on the inhibition of thermolysin by phosphorous-containing inhibitors. J. Am. Chem. Soc. 1991, 113:297-307.
13. Chen Y.L., Nielsen J., Hedberg K.D.A., Jones S., Russo L., et al. Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 898-carbaphysostigmine analogues. J. Med. Chem. 1992, 35:1429-1434.
14. Marseigne, I. and Roques, B.P. Synthesis of new amino-acids mimicking sulfated and phosphorylated tyrosine residues. J. Org. Chem.53: 3621-3624.
15. Burke T.R., Smyth M., Nomizu M., Otaka A., Roller P.P. Preparation of fluoro- and hydroxy-4-phosphonomethyl-d,l-phenylalanine suitably protected for solid phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine. J. Org. Chem. 1993, 58:1336-1340.
16. Erlenmeyer H., Willi E. Zusammenhänge zwischen Konstitution und Wirkung bei Pyrazolonderivaten. Helv. Chim. Acta 1935, 18:740-743.
17. Wallace E.M., Moliterni J.A., Moskal M.A., Neubert A.D., Marcopoulos N., et al. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. J. Med. Chem. 1998, 41:1513-1523.
18. De Lombaert S., Stamford L.B., Blanchard L., Tan J., Hoyer D., et al. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase. 22.11. Bioorg. Med. Chem. Lett. 1997, 8:1059-1064.
19. Binder D., Noe C.R., Holzer W., Baumann K. Thiophen als strukturelement physiologisch aktiver substanzen,16. Thienoisoxazole durch substitution am oximstickstoff. Arch. Pharm. 1987, 320:837-843.
20. Uno H., Kurokawa M., Masuda Y., Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anti-convulsant activities. J. Med. Chem. 1979, 22:180-183.
21. Gold-Aubert P., Melkonian D., Toribio L. Synthèses de nouvelles phényl-1-triazoline-1,2,4-ones-5 substituées en 3 et 4. Helv. Chim. Acta 1964, 47:2068-2071.
22. Alonzo R., Andrès J.I., Garcia-Lopez M.-T., de las Heras F.G., Herranz R., et al. Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide. J. Med. Chem. 1985, 28:834-838.
23. Garvey D.S., Wasicak J.T., Elliott R.L., Lebold S.A., Hettinger A.-M., et al. Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine. J. Med. Chem. 1994, 37:4455-4463.
24. 3 receptor. J. Med. Chem. 1987, 30:1535-1537.
25. Blaskó G., Major E., Blaskó G., Rózsa I., Szántay C. Pyrimido[1,6-a]pyrido[3,4-b] indoles as new platelet inhibiting agents. Eur. J. Med. Chem. 1986, 21:91-95.
26. Kardos J., Blaskó G., Simonyi M., Szántay C. Octahydroindolo[2,3-a]quinolizin-2-one, a novel structure for γ-aminobutyric acid (GABA) uptake inhibition. Eur. J. Med. Chem. 1985, 21:151-154.
27. Salituro F.G., Harrison B.L., Baron B.M., Nyce P.L., Stewart K.T., et al. 3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-d-aspartic receptor associated glycine binding site. J. Med. Chem. 1992, 35:1791-1799.
28. Calvino R., Stilo A.D., Fruttero R., Gasco A.M., Sorba G., et al. Pharmacochemistry of the furoxan ring: recent developments. Il Farmaco 1993, 48:321-334.
29. Lipinski C.A., Aldinger C.E., Beyer T.A., Bordner J., Burdi D.F., et al. Hydantoin isosteres. In vivo active spiro hydroxy acetic aldose reductase inhibitors. J. Med. Chem. 1992, 35:2169-2177.
30. Ganellin C.R. Discovery of cimetidine, ranitidine and other H2-receptor histamine antagonists. Medicinal Chemistry-The Role of Organic Chemistry in Drug Research 1993, 227-255. Academic Press, London.
31. Morin I. 3-Aryl as-triazines: Bioisostérie avec les 6-aryl pyridazines. Thesis, Université Louis Pasteur, Strasbourg 1991, 17 January.
32. Mallamo J.P., Pilling G.M., Wetzel J.R., Kowalczik P.J., Bell M.R, et al. Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J. Med. Chem. 1992, 35:1663-1670.
33. Clementi S., Cruciani G. New set of principal properties for heteroaromatics obtained by grid. Quant. Struct. Act. Rel. 1996, 15:108-120.
34. Gibson S., McGuire R., Rees D.C. Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments. J. Med. Chem. 1996, 39:4065-4072.
35. Saari W.S., Wai J.S., Fisher T.E., Thomas C.M., Hoffman J.M., et al. Synthesis and evaluation of 2-pyridone derivatives as HIV-1-specific everse transcriptase inhibitors. 2. Analogues of 3-aminopyridine-2-(1H)-one. J. Med. Chem. 1992, 35:3792-3802.
36. Langer T., Hoffmann R.D. New principal components derived parameters describing molecular diversity of heteroaromatic residues. Quant. Struct. Act. Rel. 1998, 17:211-223.
37. Almquist R.G., Chao W.R., Jennings-White C. Synthesis and biological activity of carboxylic acid replacement analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-l-proline. J. Med. Chem. 1985, 28:1067-1071.
38. - und NCN- Gruppen. Z. Anorg. Chem. 1970, 379:183-192.
39. Kwon C.-H., Nagasawa H.T., DeMaster E.G., Shirota F.N. Acyl, N-protected α-aminoacyl, and peptidyl derivatives as prodrug forms of the alcohol deterrent agent cyanamide. J. Med. Chem. 1986, 29:1922-1929.
40. Bovy P.R., Reitz D.B., Collins J.T., Chamberlain T.S., Olins G.M., et al. Nonpeptide angiotensin II antagonists: N-phenyl-1-H-pyrrole derivatives are angiotensin II receptor antagonists. J. Med. Chem. 1993, 36:101-110.
41. Marshall W.S., Goodson T., Cullinan G.J., Swanson-Bean D., Haisch K.D., et al. Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. J. Med. Chem. 1987, 30:682-689.
42. Kohara Y., Kuba K., Imamiya E., Wada T., Inada Y., et al. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole nioisosteres. J. Med. Chem. 1996, 39:5228-5235.
43. Krogsgaard-Larsen P. Comprehensive Medicinal Chemistry 1990, 493-537. Pergamon Press, London.
44. Lunn W.H.W., Schoepp D.D., Lodge D., True R.A., Millar J.D Poster No. P-041.A. LY262466, dl-2-amino-3-(4-hydroxy-1,2,5-thiazol-3-yl) propanoic acid hydrochloride, a novel and selective agonist at the AMPA excitatory amino acid receptor. XIIth International Symposium on Medicinal Chemistry 1992, 133-137. Basel: Switzerland, 13-17 September.
45. Atkinson J.G., Girard Y., Rokach J., Rooney C.S., McFarlane C.S., et al. Kojic amine-A novel γ-aminobutyric acid analogue. J. Med. Chem. 1979, 22:90-106.
46. B antagonists: novel CNS-active compounds. Perspectives in Medicinal Chemistry 1993, 259-272. VHC, Oxford.
47. Rosowsky A., Forsch R.A., Freisheim J.H., Moran R.G., Wick M. Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by l-homocysteic acid and l-cysteic acid: effect on enzyme inhibition and antitumor activity. J. Med. Chem. 1984, 27:600-604.
48. Drummond J.T., Johnson G. Convenient procedure for the preparation of alkyl and aryl substituted N-(aminoalkylacyl)sulfonamides. Tetrahedron Lett. 1988, 29:1653-1656.
49. Albright J.D., DeVries V.G., Du M.D., Largis E.E., Miner T.G., et al. Potential antiatherosclerotic agents. 3. Substituted benzoic and non-benzoic analogues of cetabon. J. Med. Chem. 1983, 26:1393-1411.
50. Buu-Hoï N.P., Lambelin G., Lepoivre C., Gillet C., Gautier M., et al. Un nouvel agent anti-inflammatoire de structure non stéroïdique: l'acide p-butoxyphénylacéthydroxamique. CR Acad. Sci. (Paris) 1965, 261:2259-2262.
51. Orzalesi G., Selleri R Pharmaceutical 2-(4-isobutylphenyl) propionohydroxamic acid. Chem. Abst. 1974, 81:120272i. German Patent 2 400 531 (24 July 1974, to Societa Italo-Britannica L. Manetti & H. Roberts e C.).
52. De Martiis F., Corsico N., Franzone J.S., Tamietto T. Valutazione farmaco-tossicologica di un nuovo agente antifiammatorio non-steroideo: l'acido indoxamico. Boll. Chim. Farm. 1975, 114:319-333.
53. Summers J.B., Masdiyasni H., Holms J.H., Ratajczik J.D., Dyer R.D., et al. Hydroxamic acid inhibitors of 5-lipoxygenase. J. Med. Chem. 1987, 30:574-580.
54. Bergeron R.J., Liu Z.-R., McManis J.S., Wiegand J. Structural alterations in desferioxamine compatible with iron clearance in animals. J. Med. Chem. 1992, 35:4739-4744.
55. De Martiis F., Franzone J.S., Tamietto T. Sintesi e proprieta antiflogistiche di alcuni acidici indolil-acetoidrossammici. Bol. Chim. Farm. 1975, 114:309-318.
56. Orzalesi G., Mari F., Bertol E., Selleri R., Pisaturo G. Anti-inflammatory agents: determination of ibuproxam and its metabolite in humans. Arzneim.-Forsch. 1980, 30:1607-1609.
57. Demay F., De Sy J. A new non-steroidal anti-inflammatory drug (NSAID) in current rheumatologic practice (oxamethacin). Curr. Ther. Res. 1982, 31:113-118.
58. Vergin H., Ferber H., Brunner F., Kukovetz W.R. Pharmakokinetik und biotransformation von Oxametacin bei gesunden probanden. Arzneim.-Forsch. 1981, 31:513-518.
59. Singh H., Chawla A.S., Kapoor V.K., Paul D., Malhotra R.K. Medicinal chemistry of tetrazoles. Progress in Medicinal Chemistry 1980, 151-183. Elsevier, Weinheim. G.P. Ellis, G.B. West (Eds.).
60. Ashton W.T., Cantone C.L., Chang L.L., Hutchins S.M., Strelitz R., et al. Non-peptide angiotensin II antagonists derived from 4H-1, 2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles. J. Med. Chem. 1993, 36:591-609.
61. Kraus J.L. Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. Pharmacol. Res. Commun. 1983, 15:183-189.
62. Schlewer G., Wermuth C.G., Chambon J.-P. Analogues tétrazoliques d'agents GABA-mimétiques. Eur. J. Med. Chem. 1984, 19:181-186.
63. Krogsgaard-Larsen P., Rodolskov-Christiansen T. GABA agonists. Synthesis and structure-activity studies on analogues of isoguvacine and THIP. Eur. J. Med. Chem. 1979, 14:157-164.
64. Krogsgaard-Larsen P. γ-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J. Med. Chem. 1981, 24:1377-1383.
65. Krogsgaard-Larsen P., Ferkany J.W., Nielsen E.O., Madsen U., Ebert B., et al. Novel class of amino acid antagonists at non-N-methyl-d-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. J. Med. Chem. 1991, 34:123-130.
66. Kraus J.L. Isosterism and molecular modification in drug design: new n-dipropylacetate analogs as inhibitors of succinic semi aldehyde dehydrogenase. Pharmacol Res. Commun. 1983, 15:119-129.
67. Lichtenthaler F.W., Heidel P. Intermediates in the formation of γ-pyrones from hexose derivatives: a simple synthesis of Kojic acid and hydroxymaltol. Angew. Chem. Int. Ed. 1969, 8:978-979.
68. Watkins J.C., Krogsgaard-Larsen P., Honoré T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharm. Sci. 1990, 11:25-33.
69. Drysdale M.J., Pritchard M.C., Horwell D.C. Rationally designed 'dipeptoid' analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. J. Med. Chem. 1992, 35:2573-2581.
70. Kinney W.A., Lee N.E., Garrison D.T., Podlesny E.J., Simmonds J.T., et al. Bioisosteric replacement of the α-amino carboxylic functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. J. Med. Chem. 1992, 35:4720-4726.
71. Gao Y., Luo J., Yao Z.J., Guo R., Zou H., et al. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J. Med. Chem. 2000, 43:911-920.
72. 1 receptor. J. Med. Chem. 1992, 35:15-27.
73. Thompkins L., Lee K.H. Comparison of analgesic effects of isosteric variations of salicylic acid and aspirin (acetylsalicylic acid). J. Pharm. Sci. 1975, 64:760-763.
74. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandine synthase by aspirin. Proc. Nat. Acad. Sci. USA 1975, 72:3073-3076.
75. Saunders J., Cassidy M., Freedman S.B., Harley E.A., Iversen L.L., et al. Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. J. Med. Chem. 1990, 33:1128-1138.
76. Sauerberg P., Kindtler J.W., Nielsen L., Sheardown M.J., Honoré T. Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships. J. Med. Chem. 1991, 34:687-692.
77. 1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 1992, 35:2263-2274.
78. Wadsworth H.J., Jenkins S.M., Orlek B.S., Cassidy F., Clark M.S., et al. Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J. Med. Chem. 1992, 35:1280-1290.
79. Street L.J., Baker R., Book T., Reeve A.J., Saunders J., et al. Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives. J. Med. Chem. 1992, 35:295-305.
80. Kozikowski A.P., Roberti M., Xiang L., Bergmann J.S., Callahan P.M., et al. Structure-activity relationship studies of cocaine: replacement of the C-2 ester group by vinyl argues against H-bonding and provides an esterase-resistant, high-affinity cocaine analogue. J. Med. Chem. 1992, 35:4764-4766.
81. Lipinski C.A. Bioisosterism in drug design. Annual Reports in Medicinal Chemistry 1986, 283-291. Academic Press, Amsterdam. D.M. Bailey (Ed.).
82. Wermuth C.G. Aminopyridazines-an alternate route to potent muscarinic agonists with no cholinergic syndrome. Il Farmaco 1993, 48:253-274.
83. 2-adrenoreceptor antagonist. J. Med. Chem. 1985, 28:1756-1759.
84. Fournier J.-P., Moreau R.C., Narcisse G., Choay P. Synthèse et propriétés pharmacologiques de sulfonylurées isostères du glibenclamide. Eur. J. Med. Chem. 1982, 17:81-84.
85. Spatola A.F. Peptide backbone modifications: structure-activity analysis of peptides containing amide bond surrogates. Chemistry and Biochemistry of Amino Acids, Peptides and Proteins 1983, 267-357. Marcel Dekker, San Diego. B. Weinstein (Ed.).
86. Fauchère J.-L. Elements for the rational design of peptide drugs. Advances in Drug Research 1986, 29-69. Academic Press, New York. B. Testa (Ed.).
87. Smith A.B., Keenan T.P., Holcomb R.C., Sprengeler P.A., Guzman M.C., et al. Design, synthesis, and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a β-strand: potential application to the design of novel inhibitors of proteolytic enzymes. J. Am. Chem. Soc. 1992, 114:10672-10674.
88. Smith A.B., Holcomb R.C., Guzman M.C., Keenan T.P., Sprengeler P.A., et al. An effective synthesis of scalemic 3,5,5-trisubstituted pyrrolin-4-ones. Tetrahedron Lett. 1993, 34:63-66.
89. Allmendinger T., Felder E., Hungerbuehler E. Fluoroolefin dipeptide isosteres. Selective Fluorination in Organic and Bioorganic Chemistry 1991, 186-195. American Chemical Society, London. J.T. Weldi (Ed.).
90. Chandrakumar N.S., Yonan P.K., Stapelfeld A., Svage M., Rorbacher E., et al. Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-l-tyrosyl-N-(3-phenylpropyl)-d-alanylamide. J. Med. Chem. 1992, 35:223-233.
91. 2 receptor antagonists. 1. Synthesis of N-cyano and N-carbamoyl amidine derivatives and their biological activities. J. Med. Chem. 1984, 27:849-857.
92. 2 receptor antagonist activity for cimetidine analogues. J. Med. Chem. 1986, 29:44-49.
93. 2-receptor antagonists. J. Med. Chem. 1982, 25:207-210.
94. Young R.C., Ganellin C.R., Graham M.J., Grant E.H. The dipole moments of 1,3-dimethylthiourea, 1,3-dimethyl-2-cyanoguanidine and 1,1-bis-methylamino-2-nitroethene in aqueous solution. Tetrahedron 1982, 38:1493-1497.
95. Young R.C., Ganellin C.R., Graham M.J., Roantree M.J., Grant E.H. The dielectric properties of seven polar amidinecontaining compounds of biological interest. Tetrahedron Lett. 1985, 26:1897-1900.
96. Wright J.L., Gregory T.F., Kesten S.R., Boxer P.A., Serpa K.A., et al. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J. Med. Chem. 2000, 43:3408-3419.
97. Larson A.A., Lish P.M. A new bio-isostere: alkylsulphonamidophenethanolamines. Nature (London) 1964, 203:1283-1285.
98. Roderick S.L., Fournié-Zaluski M.C., Roques B.P., Matthews B.W. Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. Biochemistry 1989, 28:1493-1497.
99. Büchi J., Stünzi E., Flury M., Hirt R., Labhart P., et al. Über lokalanästhetisch wirksame basische ester und amide verschiedener alkoxy-amino-benzoesäuren. Helv. Chim. Acta 1951, 34:1002-1013.
100. Bös M., Jenck F., Martin J.R., Moreau J.L., Sleight A.J., et al. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J. Med. Chem. 1997, 40:2762-2769.
101. Wilhelm M. The chemistry of polycyclic psycho-active drugs: serendipity or systematic investigation?. Pharm. J. 1975, 214:414-416.
102. Yoshimura H., Kikuchi K., Hibi S., Tagami K., Satoh T., et al. Discovery of novel and potent retinoic acid receptor α agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole. J. Med. Chem. 2000, 43:2929-2937.
103. Chenoweth M.B., McCarthy L.P. On the mechanism of the pharmacophoric effect of halogenation. Pharmacol. Rev. 1963, 15:673-707.
104. Goldman P. The carbon-florine bond in compounds of biological interest. Science 1969, 164:1123-1130.
105. Peters R.A. Biochemical Lesions and Lethal Synthesis 1963, Pergamon Press, Washington.
106. Chapman N.B., James J.W., Graham J.D.P., Lewis G.P. Chemical reactivity and pharmacological activity among 2-haloethylamine derivatives with a naphtylmethyl group. Chem. Ind (London) 1952, 805-807.
107. Vaughan J.R.J., Anderson G.W., Clapp R.C., Clark J.H., English J.P., et al. Antihistamine agents. IV. Halogenated N,N-dimethyl-N'-benzyl-N-(2-pyridyl)-ethylenediamines. J. Org. Chem. 1949, 14:228-234.
108. Schatz V.B. Isosterism and bioisosterism. Medicinal Chemistry 1963, 72-88. Interscience Publishers, Oxford. A. Burger (Ed.).
109. Fessenden R.J., Fessenden J.S. The biological properties of silicon compounds. Advances in Drug Research 1967, 95-132. Academic Press, New York. N.J. Harper, A.B. Simmonds (Eds.).
110. Tacke R., Zilch H. Sila-substitution-a useful strategy for drug design?. Endeavour, New Series 1986, 10:191-197.
111. Tacke R., Zilch H. Drug-design by sila-substitution and microbial transformations of organosilicon compounds: some recent results. L'Actualité Chimique 1986, 75-82.
112. Ricci A., Seconi G., Taddei M. Bioorganosilicon chemistry: trends and perspectives. Chimica Oggi-Chemistry Today 1989, 7:15-21.
113. Metcalf R.L., Fukuto T.R. Silicon-containing carbamate insecticides. J. Econ. Entomol. 1965, 58:1151.
114. Anonymous Zifrosilone. Drugs Fut. 1994, 19:854-855.
115. Hornsperger J.M., Collard J.N., Heydt J.G., Giacobini E., Funes S., et al. Trimethylsilylated trifluoromethyl ketones, a novel class of acetylcholinesterase inhibitors: biochemical and pharmacological profile of MDL 73,745. Biochem. Soc. Trans. 1994, 22:758-763.
116. Fessenden R.J., Coon M.D. Silicon-substituted medicinal agents. Silacarbamates related to meprobamate. J. Med. Chem. 1965, 8:604-608.
117. Tacke R. Sila-pharmaka XIX. Sila-pridinol und pridinol: darstellung und eigenschaften sowie strukturen im kristallinen und gelösten Zustand. Chem. Ber. 1980, 113:1962-1980.
118. Moberg W.K. Fungicidal 1,2,3-triazole derivatives 1985, US Patent 4 510 136 (Apr. 9, 1985 to E.I. Du Pont).
119. 2A antagonists. Bioorg. Med. Chem. Lett. 1994, 4:415-420.
120. Gotteland J.-P., Brunel I., Gendre F., Désiré J., Delhon A., et al. (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. J. Med. Chem. 1995, 38:3207-3216.
121. Gotteland J.-P., Delhon A., Junquéro D., Oms P., Halazy S. Design and synthesis of new hypocholesteremic organosilanes with antioxidant properties. Bioorg. Med. Chem. Lett. 1996, 6:533-538.
122. Heinonen P., Sipilä H., Neuvonen K., Lönnberg H., Cockroft V.B., et al. Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2-silainden-2-yl)imidazole, a silicon analogue of atipamezole. Eur. J. Med. Chem. 1996, 31:725-729.
123. Bom D., Curran D.P., Kruszewski S., Zimmer S.G., Strode J.T., et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 2000, 43:3970-3980.
124. Sommer L.H., Bennet O.F., Campbell P.G., Weyenberg D.R. Stereochemistry of hydride ion displacement from silicon. Enhanced rates at Bridgehead and 4-ring silicon atoms. J. Am. Chem. Soc. 1957, 79:3295-3296.
125. Fessenden R.J., Ahlfors C. The metabolic fate of some silicon-containing carbamates. J. Med. Chem. 1967, 10:810-812.
126. Landauer W. On the chemical production of developmental abnormalities and of phenocopies in chicken embryos. J. Cell. Comp. Physiol. 1954, 43:261-305.
127. Landauer W., Clark E.M. On the role of riboflavin in the teratogenic activity of boric acid. J. Exp. Zool. 1964, 156:307-312.
128. Browning E. Toxicity of Industrial Metals 1969, 90-97. Appleton-Century-Crofts, London. second edn.
129. Caujolle P.H.C. Structure chimique et activité spasmolytique des organoboriques. Arch. Int. Pharmacodyn. Ther. 1968, 172:467-474.
130. Mubarak S.I.M., Stanford J.B., Sugden J.K. Some aspects of the antimicrobial and chemical properties of phenyl boronate esters of chloramphenicol. Drug Dev. Ind. Pharm. 1984, 10:1131-1160.
131. Dünitz J.D., Hawley D.M., Miklos D., White D.N.J., Berlin Y., et al. Structure of boromycin. Helv. Chim. Acta 1971, 54:1709-1713.
132. Kinder D.H., Katzenellenbogen J.A. Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsine and elastase. J. Med. Chem. 1985, 28:1917-1925.
133. Alam F., Soloway A.H., Bapat B.V., Barth R.F., Adams D.M. Boron compounds for neutron capture therapy. Basic Life Sci. 1989, 50:107-111.
134. Kahl S.B., Joel D.D., Finkel G.C., Micca P.L., Nawrocky M.M., et al. A carboranyl porphyrin for boron neutron capture therapy of brain tumors. Basic Life Sci. 1989, 50:193-203.
135. Gabel D. Tumor-seeking for boron neutron capture therapy: synthesis and biodistribution. Basic Life Sci. 1989, 50:233-241.
136. Klayman D.L., Günther W.H.H. Organic Selenium Compounds: Their Chemistry and Biology 1973, Wiley-Interscience, New York.
137. Kang S.I., Spears C.P. Linear free energy relationships and cytotoxicities of para-substituted 2-haloethyl aryl selenides and bis(-chloroethyl) selenides. J. Med. Chem. 1987, 30:597-602.
138. Fischer H., Terlinden R., Löhr J.P., Römer A. A novel biologically active selenoorganic compound. VIII. Biotransformation of ebselen. Xenobiotica 1988, 18:1347-1359.
139. Parnham M.J., Graf E. Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. Biochem. Pharmacol. 1987, 36:3095-3102.